Prenetics Global (NASDAQ:PRE) CEO Danny Sheng Wu Yeung Acquires 17,181 Shares

Prenetics Global Limited (NASDAQ:PRE) CEO Danny Sheng Wu Yeung acquired 17,181 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was acquired at an average price of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the purchase, the chief executive officer directly owned 112,416 shares of the company’s stock, valued at $2,386,591.68. This trade represents a 18.04% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Danny Sheng Wu Yeung also recently made the following trade(s):

• On Thursday, August 20th, Danny Sheng Wu Yeung bought 7,500 shares of Prenetics Global stock. The shares were bought at an average cost of $18.31 per share, for a total transaction of $137,325.00.

Prenetics Global Price Performance

Shares of NASDAQ PRE traded up $1.62 during mid-day trading on Monday, hitting $21.82. The company had a trading volume of 417,652 shares, compared to its average volume of 135,502. Prenetics Global Limited has a 12 month low of $7.18 and a 12 month high of $23.63. The firm has a market cap of $368.19 million, a P/E ratio of -5.25 and a beta of 0.26. The business’s 50-day simple moving average is $19.07 and its 200-day simple moving average is $18.90.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The business had revenue of $46.49 million during the quarter, compared to analysts’ expectations of $49.85 million. As a group, sell-side analysts predict that Prenetics Global Limited will post -1.86 EPS for the current year.

Wall Street Analyst Weigh In

PRE has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a report on Friday, July 17th. Wall Street Zen upgraded Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Benchmark raised their price target on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.25.

Institutional Trading of Prenetics Global

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN acquired a new stake in Prenetics Global in the fourth quarter valued at $47,000. State of Wyoming acquired a new position in shares of Prenetics Global during the 1st quarter worth about $48,000. JPMorgan Chase & Co. acquired a new stake in Prenetics Global in the 3rd quarter valued at about $65,000. Operose Advisors LLC bought a new position in Prenetics Global during the second quarter worth about $129,000. Finally, Manatuck Hill Partners LLC bought a new position in Prenetics Global during the fourth quarter worth about $170,000. 25.01% of the stock is owned by institutional investors.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.